...as SVP and CMO, a new position. He was a senior partner at TranScrip Partners. ImmunoMolecular Therapeutics LLC...
...Staff Akcea Therapeutics Inc. ImCheck Therapeutics S.A.S. IsoPlexis Corp. Abeona Therapeutics Inc. Evaxion Biotech A/S Strongbridge Biopharma plc Sotio a.s. Rexgenero Ltd. Lyra Therapeutics Inc. ImmunoMolecular Therapeutics LLC Khondrion...

...The JDRF T1D Fund’s investment in ImmunoMolecular Therapeutics this week is the latest example of how...
...there were almost no venture capital firms investing in Type I diabetes,” Doherty said. The ImmunoMolecular...
...would we do that? Because we want to help them get financing.”  According to ImmunoMolecular...

...the DQ2 and/or DQ8 alleles, the company will also develop a DQ2 inhibitor for diabetes. ImmunoMolecular...
...lead to overly broad immunosuppression. Virobay did not respond to requests for comment. COMPANY PROFILE ImmunoMolecular Therapeutics LLC...
...I diabetes and D-methyldopa for Type I diabetes and celiac disease Companies and Institutions Mentioned ImmunoMolecular Therapeutics LLC...

...Autoimmune company ImmunoMolecular Therapeutics LLC (Broomfield, Colo.) emerged from stealth mode with a small molecule candidate that aims...
...diseases including celiac disease, for which HLA-DQ2 has been identified as an immune recognition gene. ImmunoMolecular Therapeutics LLC...

...been identified as an immune recognition gene. Mary Romeo University of Colorado HLA-DQ2 Major histocompatibility complex class II DQ8 (HLA-DQ8) ImmunoMolecular...